Covered recipient · General Payments record
JANE LEE
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$4,782.38
- Reported across 58 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,207.63 | 14 |
| Education | $99.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $300.13 | 3 |
| Janssen Biotech, Inc. | $246.14 | 4 |
| LEO Pharma Inc. | $244.00 | 3 |
| GENZYME CORPORATION | $124.99 | 1 |
| UCB, Inc. | $121.56 | 1 |
| Lilly USA, LLC | $117.27 | 1 |
| Regeneron Healthcare Solutions, Inc. | $112.81 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $39.73 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $124.99 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139926585 | CMS |
| Incyte Corporation | $111.65 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141217642 | CMS |
| Incyte Corporation | $128.75 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141241324 | CMS |
| Incyte Corporation | $59.73 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141294006 | CMS |
| Janssen Biotech, Inc. | $14.30 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078359818 | CMS |
| Janssen Biotech, Inc. | $124.09 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078359853 | CMS |
| Janssen Biotech, Inc. | $99.00 | 02/27/2024 | Education | Undisputed | 01/23/2026 | 1078359838 | CMS |
| Janssen Biotech, Inc. | $8.75 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078359865 | CMS |
| LEO Pharma Inc. | $124.98 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152639703 | CMS |
| LEO Pharma Inc. | $59.51 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152639705 | CMS |
| LEO Pharma Inc. | $59.51 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152639707 | CMS |
| Lilly USA, LLC | $117.27 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135043762 | CMS |
| Novartis Pharmaceuticals Corporation | $39.73 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087138840 | CMS |
| Regeneron Healthcare Solutions, Inc. | $112.81 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114098029 | CMS |
| UCB, Inc. | $121.56 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143297435 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.